Search results
Results From The WOW.Com Content Network
Sales and marketing efforts were supported by two large trials, the Celecoxib Long-term Arthritis Safety Study [44] (CLASS) in JAMA, and the Vioxx Gastrointestinal Outcomes Research (VIGOR). [45] The VIGOR trial was later proven to have been based on faulty data, and Vioxx was eventually withdrawn from the market. [46]
The therapeutic recommended dosages were 12.5, 25, and 50 mg with an approximate bioavailability of 93%. [12] [13] [14] Rofecoxib crossed the placenta and blood–brain barrier, [12] [13] [15] and took 1–3 hours to reach peak plasma concentration with an effective half-life (based on steady-state levels) around 17 hours.
Voluntarily withdrawn from US market because of risk of Progressive multifocal leukoencephalopathy (PML). Returned to market July 2006. Nefazodone: 2004 Europe, Australia, New Zealand and Canada [35] [36] [37] Branded version withdrawn by originator in several countries in 2007 for hepatotoxicity. Generic versions available. Still available in ...
[5] [6] It took less than eight years to develop and market the first COX-2 inhibitor, with Celebrex launched in December 1998 and Vioxx launched in May 1999. [ 7 ] [ 8 ] Celecoxib and other COX-2 selective inhibitors, valdecoxib , parecoxib , and mavacoxib , were discovered by a team at the Searle division of Monsanto led by John Talley .
On September 28, 2004, Merck notified the FDA that it was voluntarily withdrawing Vioxx from the market, and it publicly announced the withdrawal on September 30. An analysis for the period 1999–2004, based on U.S. Medical Expenditure Survey data, reported that Vioxx was associated with 46,783 heart attacks, and along with the other popular ...
Pepsi now has an 8.8 percent market share, just slightly edging out Diet Coke's market share of 8.5 percent for that second-place spot. Diet Coke had been at No. 2 since 2010, but a 6.6 percent ...
On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx.
Little is known about the Hangzhou startup behind DeepSeek, whose controlling shareholder is Liang Wenfeng, co-founder of quantitative hedge fund High-Flyer, based on records.